Bear Stearns Ups Johnson & Johnson Rating

Analyst Rick Wise says the drugmaker looks increasingly attractive for long-term investors

Bear Stearns upgraded Johnson & Johnson (JNJ ) to outperform from peer perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.